Literature DB >> 17702652

Rational design of vaccines against tuberculosis directed by basic immunology.

Stephen T Reece1, Stefan H E Kaufmann.   

Abstract

Tuberculosis represents a serious problem for public health worldwide, and effective vaccines are urgently required. This represents a significant challenge as the causative bacterial agent, Mycobacterium tuberculosis, has developed strategies to persist in infected hosts despite the presence of potent T-cell-mediated immune responses. New advances in basic immunology are giving us improved understanding of what constitutes a protective immune response and ways this response is manipulated by the bacillus. Such insights should inform us how to design more effective vaccination strategies against intracellular pathogens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17702652     DOI: 10.1016/j.ijmm.2007.07.004

Source DB:  PubMed          Journal:  Int J Med Microbiol        ISSN: 1438-4221            Impact factor:   3.473


  11 in total

1.  ESAT-6 inhibits production of IFN-gamma by Mycobacterium tuberculosis-responsive human T cells.

Authors:  Xisheng Wang; Peter F Barnes; Karen M Dobos-Elder; James C Townsend; Yoon-tae Chung; Homayoun Shams; Stephen E Weis; Buka Samten
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

2.  Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.

Authors:  Ying Xu; Wei Liu; Hongbo Shen; Jingran Yan; Di Qu; Honghai Wang
Journal:  Clin Vaccine Immunol       Date:  2009-06-10

Review 3.  The impact of mucosal infections on acquisition and progression of tuberculosis.

Authors:  S Perry; R Hussain; J Parsonnet
Journal:  Mucosal Immunol       Date:  2011-03-16       Impact factor: 7.313

Review 4.  The immunology of tuberculosis: from bench to bedside.

Authors:  Keertan Dheda; Stephan K Schwander; Bingdong Zhu; Richard N van Zyl-Smit; Ying Zhang
Journal:  Respirology       Date:  2010-04       Impact factor: 6.424

Review 5.  Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii.

Authors:  Jeffrey G Shannon; Robert A Heinzen
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

6.  Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses.

Authors:  Christiane Desel; Anca Dorhoi; Silke Bandermann; Leander Grode; Bernd Eisele; Stefan H E Kaufmann
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

7.  Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.

Authors:  Katalin A Wilkinson; Ronnett Seldon; Graeme Meintjes; Molebogeng X Rangaka; Willem A Hanekom; Gary Maartens; Robert J Wilkinson
Journal:  Am J Respir Crit Care Med       Date:  2009-07-23       Impact factor: 21.405

8.  Dietary restriction abrogates antibody production induced by a DNA vaccine encoding the mycobacterial 65 kDa heat shock protein.

Authors:  Larissa Lumi Watanabe Ishikawa; Thaís Graziela Donegá França; Fernanda Chiuso-Minicucci; Sofia Fernanda Gonçalves Zorzella-Pezavento; Nelson Mendes Marra; Paulo Câmara Marques Pereira; Célio Lopes Silva; Alexandrina Sartori
Journal:  Genet Vaccines Ther       Date:  2009-07-16

9.  The tuberculosis vaccine candidate Bacillus Calmette-Guérin ΔureC::hly coexpressing human interleukin-7 or -18 enhances antigen-specific T cell responses in mice.

Authors:  Martin Rao; Alexis Vogelzang; Peggy Kaiser; Stefanie Schuerer; Stefan H E Kaufmann; Martin Gengenbacher
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

10.  Mycobacterium tuberculosis Rv3628 drives Th1-type T cell immunity via TLR2-mediated activation of dendritic cells and displays vaccine potential against the hyper-virulent Beijing K strain.

Authors:  Woo Sik Kim; Jong-Seok Kim; Seung Bin Cha; Hongmin Kim; Kee Woong Kwon; So Jeong Kim; Seung Jung Han; Soo Young Choi; Sang-Nae Cho; Jong-Hwan Park; Sung Jae Shin
Journal:  Oncotarget       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.